Cargando…

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

INTRODUCTION: This study was conducted using an integrated retrospective database to evaluate the effectiveness of Omnitrope(®) (Sandoz) on children with growth hormone deficiency (GHD), idiopathic short stature (ISS), and Turner Syndrome (TS) who switched from a non-Omnitrope recombinant human grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rashid, Nazia, Saenger, Paul, Wu, Yi-Lin, Woehling, Heike, Frankel, Matthew, Lifshitz, Fima, Muenzberg, Michael, Rapaport, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254867/ https://www.ncbi.nlm.nih.gov/pubmed/25096555 http://dx.doi.org/10.1007/s13554-014-0017-1

Ejemplares similares

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study
por: Rapaport, Robert, et al.
Publicado: (2013)

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
por: Flodmark, Carl-Erik, et al.
Publicado: (2013)

Exogenous recombinant human growth hormone effects during suboptimal energy and zinc intake
por: Rising, Russell, et al.
Publicado: (2005)

Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study
por: Ferone, D., et al.
Publicado: (2017)

SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)
por: Schwarz, Hans-Peter, et al.
Publicado: (2019)

A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope(®)) During a Phase III Clinical Trial
por: Borrás Pérez, Victoria, et al.
Publicado: (2015)

Ten years of biosimilar recombinant human growth hormone in Europe
por: Saenger, Paul
Publicado: (2017)

SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2020)

Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
por: Schwarz, Hans-Peter, et al.
Publicado: (2016)

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
por: Iughetti, Lorenzo, et al.
Publicado: (2016)

Obesity in Children
por: Lifshitz, Fima
Publicado: (2008)

Nutrition and Growth
por: Lifshitz, Fima
Publicado: (2009)

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

Lower energy expenditures in infants from obese biological mothers
por: Rising, Russell, et al.
Publicado: (2008)

Energy expenditures & physical activity in rats with chronic suboptimal nutrition
por: Rising, Russell, et al.
Publicado: (2006)

Relationship between maternal obesity and infant feeding-interactions
por: Rising, Russell, et al.
Publicado: (2005)

Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age
por: Walczak, Mieczyslaw, et al.
Publicado: (2021)

Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program
por: Rapaport, Robert, et al.
Publicado: (2018)

Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022)

SUN-255 PATRO Children, a Multi-Center, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment: Comparing United States (US) and Rest of World (ROW) Data
por: Backeljauw, Philippe, et al.
Publicado: (2019)

Current Status of Biosimilar Growth Hormone
por: Saenger, Paul
Publicado: (2009)

Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study
por: Partsch, Carl-Joachim, et al.
Publicado: (2015)

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
por: Romer, Tomasz, et al.
Publicado: (2011)

Long‐acting growth hormone in 2022
por: Steiner, Margaret, et al.
Publicado: (2023)

Energy expenditure in chow-fed female non-human primates of various weights
por: Rising, Russell, et al.
Publicado: (2008)

Long acting growth hormone (LAGH), an update
por: Grillo, Margaret Steiner, et al.
Publicado: (2023)

Patient and clinical characteristics associated with gout flares in an integrated healthcare system
por: Rashid, Nazia, et al.
Publicado: (2015)

Quantitative Regulation of Class Switch Recombination by Switch Region Transcription
por: Lee, Chung-Gi, et al.
Publicado: (2001)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

Editorial: Controversies in growth hormone treatment and diagnosis
por: Rapaport, Robert, et al.
Publicado: (2022)

Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder
por: Saenger, Paul, et al.
Publicado: (2012)

Immunoglobulin class-switch recombination deficiencies
por: Durandy, Anne, et al.
Publicado: (2012)

Capsular Switching and Other Large-Scale Recombination Events in Invasive Sequence Type 1 Group B Streptococcus
por: Neemuchwala, Alefiya, et al.
Publicado: (2016)

AID function in somatic hypermutation and class switch recombination: AID function in somatic hypermutation and class switch recombination
por: Yu, Kefei
Publicado: (2022)

Processing of Switch Transcripts Is Required for Targeting of Antibody Class Switch Recombination
por: Hein, Katharina, et al.
Publicado: (1998)

Treatment of Pediatric Growth Hormone Deficiency With Oral Secretagogues Revisited
por: Yau, Mabel, et al.
Publicado: (2021)

Growth Hormone Stimulation Testing: To Test or Not to Test? That Is One of the Questions
por: Yau, Mabel, et al.
Publicado: (2022)

Controlled, double-blind, randomized clinical trial to evaluate the impact of fruit juice consumption on the evolution of infants with acute diarrhea
por: Valois, Sandra, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_1om5oa596ht8bbu68fj08qi8jl